Michiel Joost van Esdonk (Michiel J van Esdonk, Michiel van Esdonk)

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 21

Top Topics

Top Venues

British journal of clinical pharmacology

CPT: pharmacometrics & systems pharmacology

Journal of pharmacokinetics and pharmacodynamics

This page only lists publications with an associated author ORCID identifier.

Publications

Willem de Laat, Lisa Pagan, Robert Karl Malcolm, Maarten Wiegerinck, Victor Nickolson, Bertine W Huisman, Frederik E Stuurman, Michiel Joost van Esdonk, Naomi Klarenbeek
First-in-human study to assess the pharmacokinetics, tolerability, and safety of single-dose oxybutynin hydrochloride administered via a microprocessor-controlled intravaginal ring. Drug delivery 30 (1) (2023)
Christina Yfanti, Birgitte Vestbjerg, Juliette Van't Westende, Nils Edvardsson, Laia Meseguer Monfort, Morten Salling Olesen, Bo Hjorth Bentzen, Morten Grunnet, Boukje C Eveleens Maarse, Jonas Goldin Diness, Michiel J B Kemme, Ulrik Sørensen, Matthijs Moerland, Michiel Joost van Esdonk, Erica S Klaassen, Pim Gal, Anders G Holst
A phase 1 trial of AP30663, a K Ca 2 channel inhibitor in development for conversion of atrial fibrillation. British journal of clinical pharmacology (2023)
Willem de Laat, Lisa Pagan, Robert Karl Malcolm, Maarten Wiegerinck, Victor Nickolson, Bertine W Huisman, Frederik E Stuurman, Michiel Joost van Esdonk, Naomi Klarenbeek
First-in-human study to assess the pharmacokinetics, tolerability, and safety of single-dose oxybutynin hydrochloride administered via a microprocessor-controlled intravaginal ring. Drug delivery 30 (1) (2023)
Willem de Laat, Lisa Pagan, Robert Karl Malcolm, Maarten Wiegerinck, Victor Nickolson, Bertine W Huisman, Frederik E Stuurman, Michiel Joost van Esdonk, Naomi Klarenbeek
First-in-human study to assess the pharmacokinetics, tolerability, and safety of single-dose oxybutynin hydrochloride administered via a microprocessor-controlled intravaginal ring. Drug delivery 30 (1) (2023)
Marije E Otto, Kirsten R Bergmann, Marieke L de Kam, Kasper Recourt, Gabriël E Jacobs, Michiel Joost van Esdonk
Item Response Theory in Early Phase Clinical Trials: Utilization of a Reference Model to Analyse the Montgomery-Åsberg Depression Rating Scale (MADRS). CPT: pharmacometrics & systems pharmacology (2023)
Josephina P M Vrouwe, Ingrid M C Kamerling, Michiel Joost van Esdonk, Josbert M Metselaar, Frederik E Stuurman, Gabri van der Pluijm, Jacobus Burggraaf, Susanne Osanto
An exploratory first-in-man study to investigate the pharmacokinetics and safety of liposomal dexamethasone at a 2- and 1-week interval in patients with metastatic castration resistant prostate cancer. Pharmacology research & perspectives 9 (5) (2022)
Gerardus J Hassing, Michiel Joost van Esdonk, Gerard J P van Westen, Adam A Cohen, Jacobus Burggraaf, Pim Gal
Dose escalations in phase I studies: Feasibility of interpreting blinded pharmacodynamic data. British journal of clinical pharmacology 88 (12) (2022)
Michiel Joost van Esdonk, Jasper Stevens
The power of modelling pulsatile profiles. Journal of pharmacokinetics and pharmacodynamics 48 (3) (2021)
Boukje C Eveleens Maarse, Claus Graff, Jørgen K Kanters, Michiel Joost van Esdonk, Michiel J B Kemme, Aliede E In 't Veld, Manon A A Jansen, Matthijs Moerland, Pim Gal
Effect of hydroxychloroquine on the cardiac ventricular repolarization: A randomized clinical trial. British journal of clinical pharmacology (2021)
Amadou Samb, Matthijs D Kruizinga, Younes Tallahi, Michiel Joost van Esdonk, Willemijn van Heel, Gertjan Driessen, Yuma Bijleveld, Frederik E Stuurman, Adam A Cohen, Anton van Kaam, Timo R de Haan, Ron Mathôt
Saliva as a sampling matrix for therapeutic drug monitoring of gentamicin in neonates: A prospective population pharmacokinetic and simulation study. British journal of clinical pharmacology (2021)
Justin Jacobse, Wouter Ten Voorde, Anushka Tandon, Stefan G Romeijn, Hendrika W Grievink, Koen van der Maaden, Michiel Joost van Esdonk, Dirk Jan A R Moes, Floris Loeff, Karien Bloem, Annick de Vries, Theo Rispens, Gertjan Wolbink, Marieke de Kam, Dimitrios Ziagkos, Matthijs Moerland, Wim Jiskoot, Joke Bouwstra, Jacobus Burggraaf, Lenneke Schrier, Robert Rissmann, Rebecca Ten Cate
Comprehensive evaluation of microneedle-based intradermal adalimumab delivery vs. subcutaneous administration: results of a randomized controlled clinical trial. British journal of clinical pharmacology 87 (8) (2021)
Matthijs D Kruizinga, Rob G J A Zuiker, Kirsten R Bergmann, Annelies C Egas, Adam A Cohen, Gijs W E Santen, Michiel Joost van Esdonk
Population pharmacokinetics of clonazepam in saliva and plasma: Steps towards noninvasive pharmacokinetic studies in vulnerable populations. British journal of clinical pharmacology (2021)
Michelle L Mellion, Lucienne Ronco, Cécile L Berends, Lisa Pagan, Sander Brooks, Michiel Joost van Esdonk, Emilie M J van Brummelen, Adefowope Odueyungbo, Lorin A Thompson, Michelle Hage, Umesh A Badrising, Shane Raines, William G Tracewell, Baziel van Engelen, Diego Cadavid, Geert J Groeneveld
Phase 1 clinical trial of losmapimod in facioscapulohumeral dystrophy: Safety, tolerability, pharmacokinetics, and target engagement. British journal of clinical pharmacology (2021)
Michiel Joost van Esdonk, Jacobus Burggraaf, Marion Dehez, Piet H van der Graaf, Jasper Stevens
Quantification of the endogenous growth hormone and prolactin lowering effects of a somatostatin-dopamine chimera using population PK/PD modeling. Journal of pharmacokinetics and pharmacodynamics 47 (3) (2020)
Matthijs D Kruizinga, Willem A J Birkhoff, Michiel Joost van Esdonk, Naomi B Klarenbeek, Tomasz Cholewinski, Tessa Nelemans, Melloney J Dröge, Adam A Cohen, Rob G J A Zuiker
Pharmacokinetics of intravenous and inhaled salbutamol and tobramycin: An exploratory study to investigate the potential of exhaled breath condensate as a matrix for pharmacokinetic analysis. British journal of clinical pharmacology 86 (1) (2020)
Kim S de Valk, Marion M Deken, Henricus J M Handgraaf, Shadhvi S Bhairosingh, Okker D Bijlstra, Michiel Joost van Esdonk, Anton G T Terwisscha van Scheltinga, A Rob P M Valentijn, Taryn L March, Jaap Vuijk, Koen C M J Peeters, Fabian A Holman, Denise E Hilling, J Sven D Mieog, John V Frangioni, Jacobus Burggraaf, Alexander L Vahrmeijer
First-in-Human Assessment of cRGD-ZW800-1, a Zwitterionic, Integrin-Targeted, Near-Infrared Fluorescent Peptide in Colon Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research 26 (15) (2020)
Michiel Joost van Esdonk, Jacobus Burggraaf, Piet H van der Graaf, Jasper Stevens
Model informed quantification of the feed-forward stimulation of growth hormone by growth hormone-releasing hormone. British journal of clinical pharmacology 86 (8) (2020)
Anneke C Dijkmans, Dinemarie M Kweekel, Jaap T van Dissel, Michiel Joost van Esdonk, Ingrid M C Kamerling, Jacobus Burggraaf
The Oral Pheneticillin Absorption Test: An Accurate Method to Identify Patients with Inadequate Oral Pheneticillin Absorption. Antibiotics (Basel, Switzerland) 8 (3) (2019)
Michiel Joost van Esdonk, Ian Lindeman, Pieter Okkerse, Marieke L de Kam, Geert J Groeneveld, Jasper Stevens
Population Pharmacokinetic/Pharmacodynamic Analysis of Nociceptive Pain Models Following an Oral Pregabalin Dose Administration to Healthy Subjects. CPT: pharmacometrics & systems pharmacology 7 (9) (2018)
Michiel Joost van Esdonk, Eline J M van Zutphen, Ferdinand Roelfsema, Alberto M Pereira, Piet H van der Graaf, Nienke R Biermasz, Jasper Stevens, Jacobus Burggraaf
How are growth hormone and insulin-like growth factor-1 reported as markers for drug effectiveness in clinical acromegaly research? A comprehensive methodologic review. Pituitary 21 (3) (2018)
Michiel Joost van Esdonk, Bonnie Tai, Andrew Cotterill, Bruce Charles, Stefanie Hennig
Prediction of glycaemic control in young children and adolescents with type 1 diabetes mellitus using mixed-effects logistic regression modelling. PloS one 12 (8) (2017)